From The Editor

  1. Is Biopharma’s Response To Coronavirus Off The Mark? 3/4/2020

    As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.

  2. COVID-19: A Case For “Virtual” Biopharma? 2/27/2020

    Work-and-learn from home policies are more than employee perks. They could help thwart a pandemic. Have you adopted procedures and tools that ensure continuity when employees aren’t in the office?

  3. The Process Behind The Potential: Therapy For HPV16-Related Malignancies 2/18/2020

    HPV-related malignancies are poised to skyrocket over the next thirty+ years. Here's a look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation to treat these cancers.

  4. Update On Advanced Rapid Microbiology Methods In Biopharma 2/13/2020

    A BioPhorum survey of biopharma end-users reveals the opportunity—and the challenge—involved in the adoption of advanced rapid microbiology methods. Audrey Chang, global head of development services at BioReliance Merck; Morven McAlister, senior director at Pall Biotech; and Scott Hooper, associate director at Merck & Co Inc. break down the data.

  5. The Perilous Development Of A Potential Biologic Blockbuster 2/10/2020

    CytoDyn's leronlimab is under FDA review for Breakthrough Therapy status. Its path from forgotten molecule to near market readiness was riddled with financial and process challenges.

  6. CDER-ETP: A Resource For Innovative Biopharma Firms 1/15/2020

    The FDA’s Center for Drug Evaluation and Research’s Emerging Technology Program (CDER-ETP), is yet another step toward removing slow-moving bureaucracy and red tape that stands in the way of innovative new technologies that drive drug development. 

  7. A Disruptive Approach To Oncology Therapy Development 1/9/2020

    CureLab Oncology CEO Alex Shneider’s lament is a biopharma industry that exhibits little appetite for those discoveries made while coloring outside the lines. We caught up with him for an update on the maverick path of lead candidate Elenagen.

  8. Biosimilar Industry Advancements To Watch In 2020 1/8/2020

    Multi-biosimilar competition in the U.S. oncology space, as well as the FDA’s regulatory progress toward a more competitive insulin market were popular topics among the whole group. But these are hardly the only big events to note in this progressing industry.

  9. How BlueWillow Biologics Is Pioneering Mucosal Vaccine Tech 1/2/2020

    CPA-wielding business and finance executive Dave Peralta is leading a pioneering intranasal nano vaccine developer through the advent of next-generation immunotherapies.

  10. The Top 7 Biosimilar Developments of 2019 12/30/2019

    I normally only do the top five developments for the biosimilar industry in this annual column. But it turned out, upon reflection, that 2019 was an even more eventful year than it may have seemed as we were making our way through. So, you’re getting a whopping seven this year.